Table 11 Comparison of current study to results of Checkmate and Keynote studies
Study | Description | Current study group/antibody–scoring | χ 2 | P-value |
|---|---|---|---|---|
Keynote 59 | Gastroesophageal carcinoma | Gastroesophageal carcinomas/22C3-CPS | 142 | < 0.00001 |
Keynote 21 | Lung cancer | Lung cancer/22C3-TPS | 5 | 0.07 |
Keynote 10 | Previously treated NSCLC | Lung cancer/22C3-TPS | 103 | < 0.0001 |
Checkmate 275 | Urothelial cancer | Urothelial cancer/28-8-tumor cell expression | 0.6 | 0.81 |
Checkmate 57 | Metastatic lung cancer | Lung cancer/22C3-TPS | 0.7 | 0.40 |
Metastatic lung cancer | Metastases/22C3-TPS | 5.9 | 0.01 | |
Checkmate 141 | Recurrent or metastatic squamous cell carcinoma | Squamous cell carcinoma/28-8 tumor cells | 4.3 | 0.04 |
Checkmate 67 | Melanoma | Melanoma/28-8 tumor cells | 0.7 | 0.39 |
Checkmate 238 | Adjuvant therapy for melanoma | Melanoma/28-8 tumor cells | 24 | < 0.00001 |
